Skip to main content

Xenoview FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 17, 2023.

FDA Approved: Yes (First approved December 23, 2022)
Brand name: Xenoview
Generic name: xenon Xe 129 hyperpolarized
Dosage form: for Oral Inhalation
Company: Polarean Imaging plc
Treatment for: Diagnosis and Investigation, Imaging of Lung

Xenoview (xenon Xe 129 hyperpolarized) is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.

Development timeline for Xenoview

Dec 28, 2022Approval FDA Approves Xenoview (xenon Xe 129 hyperpolarized) for use with MRI for the Evaluation of Lung Ventilation

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.